Abstract
Elevated eye pressure is the main risk factor for glaucoma; intraocular pressure rises when the ratio between aqueous humor formation (inflow) and its outflow is unbalanced. Currently, the main goal of medical treatment is the reduction of intraocular pressure. Five main classes of topical drugs are available; they include betablockers, carbonic anhydrase inhibitors, prostaglandin derivatives, sympathomimetics and miotics. Beta-blockers and carbonic anhydrase inhibitors slow the formation of aqueous humor and may be considered as “inflow” drugs; the other three classes reduce the resistance to the drainage of aqueous humor and may be considered as “outflow” drugs. Despite the variety of drugs accessible in the market, there is a real need for ophthalmologists to have more potent medications for this disease. This review focuses on medical treatment of glaucoma with particular attention to novel molecules in pre-clinical or clinical development.
Keywords: Glaucoma, intraocular pressure, IOP lowering drugs, drug development.
Current Pharmaceutical Design
Title:Controversies in Glaucoma: Current Medical Treatment and Drug Development
Volume: 21 Issue: 32
Author(s): Claudio Bucolo, Chiara Bianca Maria Platania, Michele Reibaldi, Vincenza Bonfiglio, Antonio Longo, Salvatore Salomone and Filippo Drago
Affiliation:
Keywords: Glaucoma, intraocular pressure, IOP lowering drugs, drug development.
Abstract: Elevated eye pressure is the main risk factor for glaucoma; intraocular pressure rises when the ratio between aqueous humor formation (inflow) and its outflow is unbalanced. Currently, the main goal of medical treatment is the reduction of intraocular pressure. Five main classes of topical drugs are available; they include betablockers, carbonic anhydrase inhibitors, prostaglandin derivatives, sympathomimetics and miotics. Beta-blockers and carbonic anhydrase inhibitors slow the formation of aqueous humor and may be considered as “inflow” drugs; the other three classes reduce the resistance to the drainage of aqueous humor and may be considered as “outflow” drugs. Despite the variety of drugs accessible in the market, there is a real need for ophthalmologists to have more potent medications for this disease. This review focuses on medical treatment of glaucoma with particular attention to novel molecules in pre-clinical or clinical development.
Export Options
About this article
Cite this article as:
Bucolo Claudio, Platania Bianca Maria Chiara, Reibaldi Michele, Bonfiglio Vincenza, Longo Antonio, Salomone Salvatore and Drago Filippo, Controversies in Glaucoma: Current Medical Treatment and Drug Development, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909095553
DOI https://dx.doi.org/10.2174/1381612821666150909095553 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Metabolic Effects of Renal Denervation
Current Clinical Pharmacology The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Design and Development of Preservative Free Herbal Dosage Forms
The Natural Products Journal Theory and Application of Microdialysis in Pharmacokinetic Studies
Current Drug Metabolism Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Purinergic Signalling and Endothelium
Current Vascular Pharmacology Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Fabrication and Characterization of Ocular Phase Transition Systems for Blepharitis: A Novel Approach
Drug Delivery Letters Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition The Relationships between the Transforming Growth Factor-β 1, Age and the Ultrasound Parameters of Arterial Wall
Vascular Disease Prevention (Discontinued) Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology The Role of Fatty Acids in the Regulation of Cerebral Vascular Function and Neuroprotection in Ischemia
CNS & Neurological Disorders - Drug Targets Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Age-Related Changes and Effects of Mild Hypothermia on Carotid Artery Reactivity in Newborn Rats
CNS & Neurological Disorders - Drug Targets Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry